Biostar Pharmaceuticals, Inc.
BSPM · OTC
12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.00 | 0.01 | -0.28 |
| FCF Yield | 72.99% | 93.69% | 2.60% | 33.28% |
| EV / EBITDA | -5.23 | -0.42 | 3.85 | 4.09 |
| Quality | ||||
| ROIC | -17.01% | -53.31% | -5.50% | 0.25% |
| Gross Margin | 38.39% | 40.93% | 49.30% | 48.71% |
| Cash Conversion Ratio | -0.86 | -0.23 | 0.68 | 11.01 |
| Growth | ||||
| Revenue 3-Year CAGR | -66.14% | -19.87% | 7.59% | -16.92% |
| Free Cash Flow Growth | -15.56% | 1,217.98% | -94.43% | 319.19% |
| Safety | ||||
| Net Debt / EBITDA | -1.27 | -0.13 | 0.30 | -0.01 |
| Interest Coverage | -17.28 | -83.77 | -8.50 | 1.38 |
| Efficiency | ||||
| Inventory Turnover | 8.82 | 68.29 | 46.20 | 32.57 |
| Cash Conversion Cycle | 384.61 | 124.54 | 167.99 | 170.20 |